Filing identity and reporting period
The supplied filing is Ventrus BioSciences, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2013, not an Assembly Biosciences filing. Ventrus was a development-stage specialty pharmaceutical company developing treatments for gastrointestinal disorders.
Financial results and liquidity
- Revenue: No product revenue to date; the company’s candidates had not received FDA approval. Gross margin and operating margin are therefore not meaningful.
- Operating expenses: Research and development was $2.61 million, down 59% from $6.42 million in Q1 2012. General and administrative expense was $1.16 million, down 34% from $1.77 million.
- Profit and loss: Operating loss was $3.77 million, versus $8.19 million a year earlier. Net loss was $3.72 million, or $0.22 per share, versus $8.17 million, or $0.66 per share. The lower R&D spending chiefly reflected discontinued VEN 309 development; G&A declined primarily because of lower stock-based compensation.
- Cash flow: Operating cash used was $4.37 million, compared with $6.09 million in Q1 2012. Financing provided $20.75 million, chiefly from the February stock offering; investing cash flow was zero. Cash increased $16.38 million during the quarter.
- Balance sheet at March 31: Cash and cash equivalents were $36.87 million; current assets were $37.10 million and current liabilities $1.98 million, for working capital of about $35.12 million. Total assets were $37.10 million and stockholders’ equity $35.13 million. No debt is listed among balance-sheet liabilities.
Material changes and business developments
- In February 2013, Ventrus raised approximately $20.8 million net: approximately $15.6 million from 6.67 million common shares and $5.2 million from 220,000 Series A non-voting convertible preferred shares. Each preferred share is convertible into 10 common shares.
- Development spending shifted toward VEN 307 (topical diltiazem for anal-fissure pain): quarterly costs increased to $2.47 million from $0.35 million. VEN 309 costs fell to zero from $5.82 million after the company stopped development following an unsuccessful Phase III trial. VEN 308 (topical phenylephrine for fecal incontinence) remained a potential program, but further development plans were not settled.
- Accumulated development-stage deficit was $96.04 million. Since inception, the company had generated no revenue and reported cumulative net losses of $96.04 million.
Outlook, risks and unusual items
- Management estimated approximately $15 million to complete VEN 307 clinical development and stated that existing cash was expected to fund operations through FDA approval and initial launch and commercialization. The estimate depends on assumptions that may prove incorrect; no assurance of approval, launch, or adequate future funding was given.
- The company expected losses for at least the next two years and no product revenue for at least that period. It may need additional financing if costs, timing, or other assumptions differ; financing may be unavailable or dilutive, and could require reduced development or surrender of product rights.
- VEN 307 license obligations include royalties if commercialized and up to $20 million in regulatory milestone payments. Management anticipated the $41,500 monthly diltiazem management fee would end by year-end 2013; it reported no expected additional development-cost payments to S.L.A. Pharma as of March 31.
- A purported securities class action was filed May 9, 2013, after quarter-end, alleging misstatements about VEN 309, its market, competitors, and trial results. The company called the claims meritless and intended to defend them, but could not predict the outcome or estimate potential loss.
- After quarter-end, the company granted 500,000 restricted stock units to four employees, with vesting partly tied to share-price thresholds. Management reported disclosure controls were effective and no material first-quarter change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: this source is a Ventrus BioSciences 10-Q, despite the request metadata naming Assembly Biosciences.
- Check subsequent FDA and clinical developments for VEN 307 and any decision to pursue VEN 308; the filing’s funding-through-launch statement is management’s estimate, not a guarantee.
- Review the February offering’s dilution, including preferred-share conversion terms, and the company’s remaining share authorization and financing needs.
- Monitor the securities lawsuit and any later disclosures of claims, estimated exposure, or resolution.
- Assess actual cash burn against the stated runway and the approximately $15 million VEN 307 completion-cost estimate.